Have pharmacogenomics failed, or do they just need larger-scale evidence and more replication?

Circulation: Cardiovascular Genetics

Volumn 6, Issue 4, 2013, Pages 413-417

  Ioannidis, John P A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CITALOPRAM; DICLOFENAC; DOCETAXEL; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; PACLITAXEL; PLATINUM; TAMSULOSIN; TEMOZOLOMIDE;

ARTICLE; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HUMAN GENOME; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); GENOTYPE; PHARMACOGENETICS; REPRODUCIBILITY;

CLINICAL TRIALS AS TOPIC; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; REPRODUCIBILITY OF RESULTS;

EID: 84884506576     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000106     Document Type: Article

References (34)

1. Siontis KC, Patsopoulos NA, Ioannidis JP. Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies. Eur J Hum Genet. 2010;18:832-837.
2. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology. 2011;22:450-456.
3. Panagiotou OA, Willer CJ, Hirschhorn JN, Ioannidis JPA. The power of meta-Analysis of genome-wide association studies. Annual Rev Genomics Human Genet. 2013, in press.
4. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106:9362-9367.
5. Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, Klemm AK et al. A Catalog of Published Genome-Wide Association Studies. www.genome.gov/ gwastudies. Accessed March 20, 2013.
6. Chu AY, Guilianini F, Grallert H, Dupuis J, Ballantyne CM, Barratt BJ, et al. Genome-wide association study evaluating lipoprotein-Associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. Circ Cardiovasc Genet. 2012;5:676-685.
7. Hopewell JC, Parish S, Offer A, Link E, Clarke R, Lathrop M, et al MRC/BHF Heart Protection Study Collaborative Group. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J. 2013;34:982-992.
8. Shiffman D, Trompet S, Louie JZ, Rowland CM, Catanese JJ, Iakoubova OA, et al. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS One. 2012;7:e38240.
9. Panagiotou OA, Ioannidis JP; Genome-Wide Significance Project. What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int J Epidemiol. 2012;41:273-286.
10. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5:257-264.
11. Wadelius M, Alfirevic A. Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing. Genome Med. 2011;3:78.
12. Urban TJ. Whole-genome sequencing in pharmacogenetics. Pharmacogenomics. 2013;14:345-348.
13. Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet. 2009;85:142-154.
14. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 2012;337:100-104.
15. United States Food and Drug Administration [http://www.fda.gov/drugs/ scienceresearch/researchareas/pharmacogenetics/ucm083378.htm]. Accessed May 12, 2013.
16. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011;3:80ps16.
17. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al; PREDICT-1 Study Team. HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
18. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379:1705-1711.
19. Ioannidis JP, Khoury MJ. Are randomized trials obsolete or more important than ever in the genomic era? Genome Med. 2013;5:32.
20. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011;5:795-806.
21. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics. 2010;11:501-505.
22. Ollier W, Sprosen T, Peakman T. UK Biobank: from concept to reality. Pharmacogenomics. 2005;6:639-646.
23. McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, et al; eMERGE Team. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011;4:13.
24. Kho AN, Pacheco JA, Peissig PL, Rasmussen L, Newton KM, Weston N, et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med. 2011;3:79re1.
25. Broer L, Lill CM, Schuur M, Amin N, Roehr JT, Bertram L, et al. Distinguishing true from false positives in genomic studies: p values. Eur J Epidemiol. 2013;28:131-138.
26. Kitsios GD, Tangri N, Castaldi PJ, Ioannidis JP. Laboratory mouse models for the human genome-wide associations. PLoS One. 2010;5:e13782.
27. Ioannidis JP, Kavvoura FK. Concordance of functional in vitro data and epidemiological associations in complex disease genetics. Genet Med. 2006;8:583-593.
28. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748-752.
29. Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013;9:e1003348.
30. McGeachie MJ, Stahl EA, Himes BE, Pendergrass SA, Lima JJ, Irvin CG, et al. Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes. Pharmacogenet Genomics. 2013;23:324-328.
31. Witte JS. Rare genetic variants and treatment response: sample size and analysis issues. Stat Med. 2012;31:3041-3050.
32. Asimit J, Zeggini E. Rare variant association analysis methods for complex traits. Annu Rev Genet. 2010;44:293-308.
33. Evangelou E, Ioannidis JP. Meta-Analysis methods for genome-wide association studies and beyond. Nat Rev Genet. 2013;14:379-389.
34. Ioannidis JP. Mega-Trials for blockbusters. JAMA. 2013;309:239-240.